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Abstract: Chemotherapy efficacy is strictly limited by the resistance of cancer cells. The ω-3
long chain polyunsaturated fatty acids (ω-3 LCPUFAs) are considered chemosensitizing agents
and revertants of multidrug resistance by pleiotropic, but not still well elucidated, mechanisms.
Nowadays, it is accepted that alteration in gene expression, modulation of cellular proliferation and
differentiation, induction of apoptosis, generation of reactive oxygen species, and lipid peroxidation
are involved in ω-3 LCPUFA chemosensitizing effects. A crucial mechanism in the control of
cell drug uptake and efflux is related to ω-3 LCPUFA influence on membrane lipid composition.
The incorporation of docosahexaenoic acid in the lipid rafts produces significant changes in their
physical-chemical properties affecting content and functions of transmembrane proteins, such as
growth factors, receptors and ATP-binding cassette transporters. Of note, ω-3 LCPUFAs often
alter the lipid compositions more in chemoresistant cells than in chemosensitive cells, suggesting a
potential adjuvant role in the treatment of drug resistant cancers.
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1. Introduction
Several epidemiological studies have highlighted an association between long chain ω-3
polyunsaturated fatty acids (ω-3 LCPUFAs) and incidence of cancers of the breast [1], colon [2],
prostate [3], liver [4], and pancreas [5]. Moreover, the ω-3 PUFAs have been shown to improve the
efficacy of chemotherapy and radiation against cancer. For example, the efficacy of doxorubicin [6],
epirubicin [7], 5-fluorouracil [8], mitomycin C [9], arabinosylcytosine [10], tamoxifen [11], and
irinotecan/CPT-11 [12] and of radiation therapy [13] has been shown to be enhanced by ω-3
PUFA association.
Recently, the results of randomized controlled clinical trials supplementing cancer patients with
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) during chemotherapy and radiotherapy
have been summarized by de Aguiar Pastore Silva et al. [14]. Overall, those studies demonstrated
that patients benefit from the combination ofω-3 LCPUFAs and chemotherapy; for instance, fish oils
induce weight maintenance or gain and immunomodulation; these achievements reduce inflammation,
even when associated with cellular immunosuppression caused by radiotherapy and chemotherapy.
The success of chemotherapy always depends on intrinsic or acquired drug resistance of cancer
cells. Tumors are able to tune drug uptake and efflux, acquire qualitative and quantitative alterations
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of the drug target, increase the efficiency of DNA damage repair systems, and enhance cell death
evasion mechanisms, contributing to drug resistance with pleiotropic mechanisms [15].
This review will summarize the evidences sustaining the role ofω-3 LCPUFAs as agents inducing
chemosensitization and/or reversing multidrug chemoresistance. The key mechanisms proposed for
these effects, with particular attention paid to the impact ofω-3 LCPUFAs on membrane architecture
and consequences on drug uptake/efflux and transporter activity, will be discussed.
2. In Vitro Evidences ofω-3 LCPUFA’s Positive Effects on Chemosensitization
In vivo and in vitro studies indicate thatω-3 LCPUFAs enhance the sensitivity of cancer cells to
chemotherapy [10,16–18].
As early as 1979, Burns et al. [19] observed that in L1210 leukemia cells,ω-3 LCPUFA changed
plasma membrane fatty acid composition and affected methotrexate transport. The cells, isolated from
animals fed withω-3 LCPUFA-enriched oil, had a lower kinetic constant for methotrexate transport
than those isolated from animals fed with a saturated-enriched oil.
Later, Guffy et al. [20] demonstrated that L1210 leukemia cells, grown in medium with DHA,
were more sensitive to the adriamycin (ADR) cytotoxicity than cells grown in medium with oleic
acid or without fatty acids. In the same period, Ziljlstra et al. [21] showed that also in GLC4 cell line,
derived from human small-cell lung carcinoma, the intracellular level of ADR increased when the
cancer cells are cultured in DHA-supplemented medium. Furthermore, the drug uptake increased
in ADR-resistant cells to a level equal to that of sensitive GLC4 cells. The increased ADR content
and cytotoxicity were attributed to the higher levels of DHA and to the significant modifications
in plasma membrane phospholipid (PL) composition. In particular, Guffy et al. [20] sustained that,
when cell plasma membrane PLs are enriched with ω-3 LCPUFAs, cells become more sensible to lipid
peroxidation and more susceptible to membrane damage.
On the same line, Ikushima et al. [22] and Das et al. [23] demonstrated that DHA is also able to
increase vincristine cytotoxicity and its uptake in neuroblastoma and cervical cell lines.
In addition, Sturlan et al. [24] showed that DHA strongly increases arsenic trioxide
(As2O3)-mediated apoptosis in the acute myeloid leukemia. As2O3 has been used for the treatment
of acute promyelocytic leukemia (APL) HL60 cells. Different mechanisms have been suggested to
explain the anti-leukemic activity of As2O3, but the generation and accumulation of reactive oxygen
species (ROS) is likely the most involved one. Indeed, ROS intracellular accumulation determined the
disruption of the mitochondrial membrane potential with the release of cytochrome c, activation of
caspases’ cascade, and apoptosis. In particular, Sturlan’s research indicated that the co-treatment of
HL60 cells with As2O3 and DHA increases amounts of ROS and thiobarbituric acid reactive substances
(TBARSs), reduces the mitochondrial potential, and activates caspase-3 inducing apoptosis. TBARSs
are one of the most widely used markers of lipid peroxidation and are generated in the presence of
malondialdehyde (MDA), a reactive aldehyde produced by lipid peroxidation of polyunsaturated
fatty acids.
As2O3 was also used to treat solid cancers, such as neuroblastoma, head and neck cancer, gastric,
prostate, and renal carcinoma. In solid tumors, the production and accumulation of ROS appear to be
the key mechanism responsible for As2O3 cytotoxic action [25]. Nevertheless, clinically achievable
dosages of As2O3 are not effective in all tumor types; for this reason, several in vitro studies have been
aimed to enhance As2O3 cytotoxic effects without increasing its concentration. In several preclinical
studies, exogenous PUFAs sensitized tumors cells to ROS-inducing anticancer drugs, such as As2O3.
Baumgartner et al. [26] tested breast (MDA-MB-468, SKBR-3, MCF7), cervical (HeLa), ovarian (SKOV-3,
ES-2), colon (HT29, SW-620, LS-174T), prostate (PC-3), and pancreatic (PANC1) cancer cell lines that
were resistant to As2O3 or DHA as single agents. Interestingly, their combination reduced viability in
SKBR-3, HT29, SW-620, LS-174T, SKOV-3, and PC-3 cells and significantly increased TBARSs.
In 2005, Menendez et al. [27] demonstrated that ω-3 LCPUFAs enhance chemosensitivity by
their increasing peroxidative processes and regulating oncoprotein expression. γ-linolenic acid (GLA)
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resulted in the most potent PUFA increasing paclitaxel toxicity followed by α-linolenic acid, EPA, and
DHA, while linoleic acid (LA) had no effects. The authors sustained that there was a strong synergistic
cytotoxic effect of DHA and paclitaxel or docetaxel in MDA-MB-231 cells. Moreover, the exposure of
BT-474 or SK-BR3 cells to DHA for 24 h reduced p185Her/neu oncoprotein expression up to 78% in
BT-474 and to 38% in SK-BR3 cells compared to untreated cells.
The co-treatment DHA and cisplatin was used on human small lung carcinoma GLC4 cell line
and its cisplatin-resistant counterpart by Timme-Bosscha et al. [28]. DHA caused a three-fold decrease
of cisplatin resistance in cells refractory to the drug. This work suggested that DHA incorporation in
cell membrane PLs could increase intracellular cisplatin content, enhancing DNA damage induced by
the inter-strand cross-links and nucleotide adducts produced by cisplatin.
3. Mechanisms Proposed for Chemosensitizing Effects ofω-3 LCPUFAs
The specific mechanisms involved in ω-3 LCPUFA chemosensitizing effects are not fully
understood, but nowadays, alteration in gene expression [29], modulation of cellular proliferation [30]
and differentiation [31], induction of apoptosis [32], increase in drug transport across the cell membrane,
generation of reactive oxygen species (ROS), and lipid peroxidation have been reported (Figure 1).
For example, lipid peroxidation is one of the major mechanisms involved in doxorubicin cytotoxicity,
together with topoisomerase II inhibition and ROS production [33]. Anthracycline cardiotoxicity
represents a major problem for chemotherapy, underlying that the major mechanism is related
to drug interference on the respiratory chain and consequent oxidative stress [34]. Since DHA,
which has six double bonds, is easily subjected to peroxidation, the increase in the membrane
unsaturation index produced by DHA incorporation enhances the ROS content generated from
doxorubicin metabolism [35]. This hypothesis is sustained by in vivo and in vitro studies that
highlight the correlation between DHA supplementation and increased oxidative stress due to higher
lipid peroxidation.
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Figure 1. Proposed mechanisms for ω-3 LCPUFA anticancer effects. LCPUFA—long chain 
polyunsaturated fatty acids; EPA—eicosapentaenoic acid; DHA—docosahexaenoic acid. 
In this context, Vibet et al. [36] demonstrated that the sensitization of breast cancer MDA-MB-
231 cells to doxorubicin by DHA is related to a marked decrease in glutathione peroxidase (GPx), the 
major antioxidant enzyme that uses glutathione as a reductive agent. In particular, the decrease in 
GPx1 activity in MDA-MB-231 cells was associated with a decreased protein level but not with a 
decreased mRNA, suggesting a post-transcriptional DHA effect. GPx might be damaged by lipid 
peroxidation products generated in breast cancer cells treated with DHA and doxorubicin. These 
oxidant products might reduce GPx activity, probably modifying the selenocysteine residue of the 
enzyme active site [37]. As a consequence, the inactivated enzyme is degraded by proteases. In the 
same study, GPx1 activity decreased also in rat tumors after supplementation with EPA/DHA or 
DHA alone, and this reduction was again associated to an increase of chemosensitivity to 
anthracyclines. 
Fig re 1. Proposed mechanisms forω-3 LCPUFA anticancer effects. LCPUFA—long chain polyunsaturated
fatt acids; EPA—eicosapentaenoic acid; DHA—d cosahexaenoic acid.
In this context, Vibet et al. [36] demonstrated that the sensitization of breast cancer MDA-MB-231
cells to doxorubicin by DHA is related to a marked decrease in glutathione peroxidase (GPx), the major
antioxidant enzyme that uses glutathione as a reductive agent. In particular, the decrease in GPx1
activity in MDA-MB-231 cells was associated with a decreased protein level but not with a decreased
mRNA, suggesting a post-transcriptional DHA effect. GPx might be damaged by lipid peroxidation
products generated in breast cancer cells treated with DHA and doxorubicin. These oxidant products
might reduce GPx activity, probably modifying the selenocysteine residue of the enzyme active site [37].
As a consequence, the inactivated enzyme is degraded by proteases. In the same study, GPx1 activity
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decreased also in rat tumors after supplementation with EPA/DHA or DHA alone, and this reduction
was again associated to an increase of chemosensitivity to anthracyclines.
One of the most important biological functions of ω-3 LCPUFAs is their role as precursors of
bioactive lipid mediators, such as eicosanoids and docosanoids (Figure 2). ω-3 LCPUFAs and their
metabolites act as second messengers when inserted in the cell membrane. Following the binding
of growth factors and hormones to membrane receptors, phospholipase A2 (PLA2) is activated and
releases dihomo-γ-linolenic acid (DGLA, C20:3,ω-6), arachidonic acid (AA, C20:4,ω-6), EPA (C20:5,
ω-3) and DHA (C22:6,ω-3) from the sn-2 position of PLs. These fatty acids are optimal substrates for
eicosanoid biosynthesis mediated by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450
monoxygenase (CYP). High levels ofω-6-derived prostaglandins (PGs) and/or high levels of COX2
have been reported in many human cancers, including those of the breast, cervix, lung, skin, colon,
and prostate [38,39], and COX2 inhibitors, such as celecoxib, indomethacin, aspirin, and piroxicam,
have been used in experiments aimed to reduce carcinogenesis. The combination of these drugs at
low concentrations with proper dietary supplements has been suggested to improve the antitumor
effects and decrease the side effects. Negi et al. [40] showed that the combination of celecoxib andω-3
LCPUFAs is more effective in the treatment of experimentally induced mammary cancers: this effect
can be attributed to modifications in redox signaling, changes in c-myc, and p53 expression, apoptosis,
and proliferation. In addition, Reddy et al. [41] showed that low doses of celecoxib, associated with a
diet containing 10% mixed lipids and 10% fish oil, significantly reduced COX2 activity and expression,
and colon cancer incidence compared with low doses of celecoxib associated with a Western-style diet,
including saturated fats of animal origin as well asω-6 LCPUFAs.
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Tx—thromboxan ; HpETE—hydroperoxy eicosatetraenoic acid; HpEPE—hydroperoxy
icosapentaenoic cid; EpETE—epoxy eicosatetraenoic acid; DiHETE—dihydroxy eicosatetraenoic
a id; HEPE—hydroxy eicosapentaenoic acid; HpDHA—hydroperoxy ocosahexaenoic acid;
HDHA—hydr xy docosahexaenoic acid; EpDPE—ep xy docosapentaenoic acid; DiHDPE dihy r
i i ; li i ;
The inhibition of carcinogenesis induced by ω-3 LCPUFAs is also mediated through the
activation of retinoid X receptors (RXR) and peroxisome proliferator activated receptor (PPAR) [42].
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Indeed, Narayanan et al. [43] suggested that a combination of DHA and celecoxib inhibits the
carcinogenesis process in three prostate cancer cell lines (LNCaP, DU145, and PC-3) through multiple
pathways that involve PPARγ, RXRα, and nuclear factor κB (NF-kB) activity. NF-kB is an inducible
transcription factor responsible of regulation of several inflammation- and cancer-related gene
expression. The co-treatment with DHA and celecoxib significantly reduces the nuclear translocation
of NF-κB-p65 component and blocks p65-induced transcription of genes related to cancer progression.
Moreover, ω-3 LCPUFAs inhibit the cleavage of inactive to active sterol response element binding
protein 1c (SREBP-1c): this event reduces the synthesis of fatty acids that are the main energy source in
prostate cancer, where androgens upregulate fatty acid synthase enzyme (FASN) [44,45]. SREBP-1c
is a positive regulator of FASN expression through binding elements in the FASN promoter [46].
The inhibition of SREBP-1c causes the intracellular accumulation of cholesteryl esters and thus
promotes cell cycle arrest [47].
Emerging data also sustain the key role of the gut microbiome in mediating the ω-3 LCPUFA
beneficial effects on immune and inflammation processes that increase the chemo response. The gut
microbiome regulates drug metabolism and functionality and is modified in cancer patients [48].
In murine models,ω-3 LCPUFA incorporation in enterocyte membrane PLs determines changes in
microbiome composition and exerts protective effects [49]. Indeed, alterations in the host microbiome
might change chemotherapy sensitivity and improve pharmacological success. Unfortunately, the data
on humans are still limited, and further studies are needed to demonstrate the complex and potential
interplay betweenω-3 LCPUFAs and gut microbiome [50].
It is noteworthy that PUFA incorporation greatly affects cell membrane fluidity and structure,
especially in membrane microdomains or lipid rafts. The plasma membrane regulates many cell biology
aspects, such as morphogenesis, proliferation, migration, differentiation, secretion, and apoptosis.
Several studies indicate that ω-3 LCPUFA incorporation in the membrane bilayer may determine
dramatic changes in physical–chemical properties, significantly lowering cholesterol solubility [51] and
changing the activity of transmembrane proteins, such as growth factors, transporters, and G-protein
coupled membrane receptors [52].
4. ω-3 LCPUFA Impact on Cell Membrane Function and Lipid Raft Organization
Recently, specific membrane proteins whose activity is modulated by changes in membrane
environment emerged as potential therapeutic targets in cancer treatment. This novel approach,
defined “membrane lipid therapy” [53], is based on the hypothesis that the use of specific lipids might
alter cancer membrane composition and structure, dismantling lipid raft architecture and altering
the localization and activity of membrane-associated proteins and down-stream pathways that are
crucial for tumor cell growth (Figure 1). The chemical–physical properties of cellular membrane
not only influence protein functions but also modify the recruitment and activity of peripheral,
amphitropic membrane proteins that interact with membrane lipids [54]. Membrane lipids interact
with hydrophobic moieties and residues of membrane proteins by lipid–lipid and lipid–protein
interactions. For instance, the ATP Binding Cassette (ABC) transporter activity is closely related to
membrane lipid environment: changes in PL and cholesterol content, as well as changes in PL fatty
acid composition, might modify the membrane surface properties [55].
Indeed, biological membranes represent two-dimensional solutions where lipids are packed with
transmembrane proteins [56] and interact with extrinsic membrane proteins. The main membrane lipid
components, including sterols (especially cholesterol), sphingolipids (in particular, sphingomyelin—SM),
PLs, such as phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), and
phosphatidylcholine (PC), contribute to the stabilization of membrane architecture.
Cancer cells are characterized by an intense lipid biosynthesis that supports the building of new
membranes that work to sustain neoplastic proliferation [57]. According to the existing literature,
membrane fatty acid and PL profiles of breast cancer are different compared to normal tissues: breast
tumors are characterized by a striking increase in membrane PC and PE, coupled with an increase in
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PL-induced cell signaling. In addition, an increase of saturated fatty acid-containing PC (16:0/16:0)
was correlated with poorer overall survival [58]. Saturated fatty acids make the cell membrane less
fluid and their higher content was associated to tumor aggressiveness and chemoresistance [59,60].
The fatty acid length and unsaturation degree might modulate membrane fluidity, phase behavior,
permeability, membrane fusion, lateral pressure, and flip-flop dynamics, perturbing the protein–lipid
interactions in plasma membranes. The increased unsaturation of PL acyl chains improves their
flexibility due to rapid isomerisation [61]; moreover, their fatty acid acyl chain composition modulates
the activity of growth and survival signaling pathways.
Cancer cells might acquire fatty acids, not only through de novo synthesis, but also through uptake
of exogenous fatty acids obtained by diet or released by cancer-associated adipocytes. Exogenous fatty
acids may alter membrane organization if they are integrated in the membrane either as free fatty acids
(FFAs) or as constituents of PLs.
Our researches have demonstrated that ω-3 LCPUFA incorporation into cell membrane PLs
may alter membrane fluidity, modulate cell signaling [51,62], and enhance ROS production and lipid
peroxidation [36]. The PUFA-enriched membranes are thinner and have higher fluidity compared to
saturated membranes. Moreover, ω-3 and ω-6 PUFAs display significant differences related to the
different saturated chain lengths, which are usually longer inω-6 PUFAs [63,64].
ω-3 LCPUFAs may alter the optimal protein conformation by changing the membrane’s
biochemical–biophysical properties. In the last few years, our group has accumulated several
evidences showing that ω-3 LCPUFAs, especially DHA, are incorporated in breast cancer membranes
with different specificity for each PL moiety: the enrichment is significant especially in PE, PI, and
PC [51]. Biochemical and biophysical approaches have confirmed that DHA incorporation causes
morpho-dimensional changes in plasma membranes, in particular in detergent-resistant domains
or lipid rafts [62,65]. Lipid rafts are dynamic structures characterized by a relative rigidity and
reduced fluidity compared with the surrounding plasma membrane, and may rapidly assemble and
disassemble, leading to a dynamic segregation of proteins [66]. They are enriched in cholesterol and
sphingo- and glycerol-lipids containing saturated fatty acids, and contain several receptors, channels,
and transporters, whose localization in raft or non-raft regions modulates their function. In cancer cells,
many signaling proteins and receptors regulating pro-oncogenic and apoptotic pathways during the
early, advanced, and metastatic stages of tumorigenesis are localized in lipid rafts [67]. Furthermore,
lipid rafts and their main component, cholesterol, are quantitatively higher within the membrane of
cancer cells than in normal cells [68].
ω-3 LCPUFAs and their metabolites are inserted into lipid rafts with different yields, altering
fatty acid composition without decreasing the total percentage of saturated fatty acids typical of rafts.
Interestingly, estrogen-resistant breast cancer MDA-MB-231 cells, which display the highest content
of cholesterol and saturated fatty acids, had the lowest incorporation of DHA, likely due to sterical
hindrance reasons; nevertheless, DHA was able to decrease cholesterol concentration in lipid rafts
(Figure 3). Moreover, in two breast cancer cell lines (MCF-7 and MDA-MB-231), the DHA treatment
determined a 20–30% decrease in lipid rafts. It is worth noting that, after DHA incorporation, lipid
rafts exhibited different height ranges [51]. These alterations influenced the conformation of resident
proteins and switched signaling proteins on or off [69].
In conclusion, ω-3 LCPUFAs might dismantle the lipid raft structure and thereby the protein
lateral distribution (Figure 3). The poor affinity between ω-3 PUFAs and cholesterol determines a
shift of cholesterol out of the raft, inducing de-clustering of membrane microdomains. ω-3 LCPUFA
incorporation in membrane microdomains determines a re-localization of raft-associated proteins, e.g.,
it induces the shift of proteins from rafts into non-rafts or in cytosolic compartment. For instance,
ω-3 PUFA acyl chain enrichment in lipid rafts and the subsequent raft de-clustering force the major
histocompatibility complex (MHC) class I proteins to shift from rafts into non-rafts compartments [70].
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i re 3. DHA impact on lipid raft structure. DHA inc rporation in membrane affects lipid
raft organization inducing a shift from cholesterol/saturated fatty acid-rich domains to ω-3
LCPUFA-rich/cholesterol-poor domains, which exhibit different height ranges.
Further ore, the specificity of P F incorporation ithin PL oieties ight influence the
synthesis of PUFA-derived mediators (such as prostaglandins, prostacyclins, leukotrienes, resolvines,
and protectines) and signal transduction depending on these metabolites.
By altering membrane organization,ω-3 PUFAs, in particular DHA, affect anticancer drug uptake,
either by increasing sensitization of cancer cells or by modulating chemoresistance.
. -3 LCP F s as everta ts f lti r sist : I it i
, i ti l t i lt s r i t t r if ti
n as multidrug resistance (MDR), is one of the most serious problems encountered during
chemotherapy. MDR can be present at th diagnosis or can be induced by the s lective pressure of
ch motherapy and r lies on diff rent mechanisms, such as increased drug efflux, reduc d drug uptake
owing to changes in lipid membrane composition, increased drug seque tration within endo-lysosomes
foll wed by exocytosis, nhanced metabolic i activation of the drug, nd qua titative or qualitative
ch ges in the dr g target [71]. Th most common event characterizing MDR cells is the ove expression
of ABC tran porters, such a P-glycoprotein (Pgp), MDR-related proteins (MRPs), and breast cancer
resistance protein (BCRP). Together, they efflux lassical chemotherapeutic agents ( .g., anthracyclines,
taxanes, Vinca alkaloids, epipodophyllotoxins, topotecan, and methotrexate) and targeted-therapies
(e.g., imatinib, dasatinib, lapatinib, gefitinib, sorafenib, and erlotinib), limiting the r ntracellular
accumulation and cytotoxicity [72].
i -3 F iti ti i - siti e r ll ,
t t to analyze whether and how they have b nefit as MDR-reversing agents. In erestingly,
ω-3 LCPUFA effects appeared rath r selective for chemoresistant cells because they induced
strong chemosensitization in cells with an acquired chemoresis ant phenotype compared with
parental clones [21,73] and in non-transformed c lls [74]. The chemosensitizing effects,
however, re not comparable between diff rent tumors, because differ nt cancer ell lines, even if
derived from the sa e tis ue, have different metabolic pathways for ω-3 PUFAs [75]; such variability
may explain the discrepancies obtained by using different PUFAs and different cancer cells.
ω-3 LCPUFAs act as MDR reversing tools by pleiotropic mechanisms. Since they are well
incorporated in plasma membran PLs and in particular in lipid rafts, this was one of the first
mechanisms investigated. ω-3 LCPUFAs incorporation was correlated wi h an increased ratio between
drug uptake a d drug fflux [23]. Intere tingly, the changes in lipid compositions i duced by ω-3
LCPUFAs are more pronounced in chemoresistant cells than i chemosensitive cells [21], likely as a
consequence of the different membrane co position that char cterizes the two cell populations [76].
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An increased incorporation of saturated fatty acids consequent to the de novo lipogenesis has been
associated with an increased resistance to doxorubicin [60]. Opposite effects should be expected when
unsaturated fatty acids are incorporated in tumor cell plasma membranes. Indeed, for drugs entering
cells by passive diffusion, such as anthracyclines, Vinca alkaloids, and purine analogues, an increased
membrane fluidity favored drug uptake [23,77,78]. In Pgp-overexpressing/vincristine-resistant
neuroblastoma cells, DHA and GLA increased the intracellular retention of the drug. This event
was not due to changes in vincristine efflux, but to the inversion of PUFAs/mono-unsaturated fatty
acids (MUFAs) ratio in plasma membrane [23], suggesting that an enhanced uptake, more than a
reduced efflux, was responsible for the higher accumulation of vincristine. This conclusion, however,
was partially in contrast with the experimental evidences gathered in doxorubicin-resistant breast
cancer cells and in vinblastine-resistant nasopharyngeal cancer cells: in both models, DHA reduced the
efflux of the Pgp substrate rhodamine 123 [79], leading to the hypothesis that the higher accumulation
of doxorubicin and vinblastine detected in DHA-treated cells was due to their reduced efflux.
As noted above, several ABC transporters mediating MDR are highly sensitive to changes
in the lipid plasma membrane. Pgp activity for instance is activated by a saturated fatty acid
(SFA)-rich environment and is inhibited by increased levels of MUFAs and PUFAs in the plasma
membrane [80]. The depletion of SFAs from drug-resistant cell membranes also decreased the amount
of Pgp within lipid-rafts [80], where the protein is abundant and active [81,82]. We recently reported
that DHA and EPA were highly incorporated in the lipid rafts of colon cancer HT9/MDR cells [73]:
following this incorporation, they reduced the amount of total membrane- and lipid raft-associated
Pgp and MRP1 (another ABC transporter enriched in rafts [83]), restoring the chemosensitivity to
doxorubicin and irinotecan. These MDR-reversing effects were peculiar ofω-3 LCPUFAs, not of the
ω-6 arachidonic acid: ω-3 LCPUFAs are indeed highly flexible structures and, compared with ω-6
LCPUFAs, can produce a stronger disassembly of the ordered lipid raft structure. Not all the ABC
transporters contained in lipid rafts, however, are inhibited by ω-3 LCPUFAs: lipid raft-associated
BCRP, for instance, was increased in DHA-treated cells [73]. BCRP has a less hydrophobic structure
than Pgp and MRP1 [71]; in this case, the enrichment of ω-3 LCPUFAs might favor the retention of
BCRP in raft compartments instead of promoting its shift in non-raft fractions. According to these data,
ω-3 LCPUFAs should be considered able to reverse the resistance towards Pgp and MRP1 substrates.
Their efficacy in reversing the resistance towards substrates of other ABC transporters that are not
localized in lipid rafts or dependent upon the membrane fluidity has not been clarified. According to
the evidences accumulated on MDR cells,ω-3 LCPUFAs are not general ABC transporter inhibitors:
their efficacy appears restricted to selected groups of chemotherapeutic drugs and ABC transporters.
Since each drug can be effluxed by more than one ABC transporter [71] and MDR cells often express
more than one transporter, this consideration freezes the enthusiasm of using ω-3 LCPUFAs as a
panacea for MDR tumors.
Besides SFAs, cholesterol is a second component abundant in lipid rafts. Of note, cholesterol
content is higher in the plasma membrane of chemoresistant cells than of chemosensitive cells [73,84].
Pgp activity is strictly dependent on membrane cholesterol: cholesterol depletion induces the shift of
Pgp from lipid rafts to non-lipid raft compartment [85,86] and reduces Pgp efflux activity [84]. DHA
and EPA, which were well incorporated in lipid rafts, displaced cholesterol from the raft fractions
of colon cancer HT29/MDR cells [73]: in agreement with other experimental observations [85,86],
the decrease in cholesterol displaced Pgp from lipid rafts and lowered its activity [73]. MDR cells
have a higher rate of synthesis of cholesterol and isoprenoids, which increase the expression of
Pgp by activating the transcriptional axes Ras/ERK/HIF-1α and RhoA/RhoA kinase/HIF-1α [87].
Interestingly, besides reducing the cholesterol amount in lipid rafts, DHA and EPA also reduced the
endogenous synthesis of cholesterol in colon cancer HT29/MDR cells. Indeed, they allosterically
activated the E3-ubiquitin ligase Trc8, which promotes the degradation of the cholesterol-pacemaker
enzyme 2-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR) [73]. This effect was specific
to ω-3 LCPUFAs, because ω-6 AA was ineffective. This discrepancy may be due to the different
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tridimensional conformation ofω-3 andω-6 LCPUFAs that makes only the former suitable allosteric
activators of Trc8. The reduction of the endogenous cholesterol synthesis further contributed to the
depletion of cholesterol from the plasma membrane, reducing the activity of Pgp and overcoming the
resistance to the Pgp substrates doxorubicin and irinotecan [73] (Figure 4).
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Although the changes in drug uptake and efflux have been primarily considered responsible for
the chemosensitization induced by ω-3 LCPUFAs, other biochemical mechanisms inducing MDR,
such as the activity of detoxifying and in activating/inactivating enzyme, can be modulated by
ω-3 LCPUFAs. Many chemotherapeutic drugs, including anthracyclines and platinum salts, are
metabolized and effluxed as glucuronic acid-, GSH- or sulfate-conjugates via MRP1 [95]. The gene
profiling analysis of colon cancer cells pointed out that DHA and EPA downregulated specific isoforms
of glucuronyltransferase, glutathione S-transferase (GST), and sulfotransferase, as well as members
of the cytochrome P450 family [96]: such reduction of Phase I and Phase II enzymes is expected to
reduce the metabolic inactivation of chemotherapeutic drugs and their subsequent efflux, thereby
increasing the intracellular accumulation of the active agents/metabolites. A robust expression pattern
of antioxidant enzymes is also protective towards the oxidative damages induced by doxorubicin
and cisplatin, and is associated with the MDR phenotype [97]. Interestingly, DHA has been reported
to reverse doxorubicin resistance in breast cancer MDA-MB-231 cells by decreasing the activity of
GPx [36]. This effect, however, cannot be generalized, since GPx was unaffected by DHA in other breast
cancer cell lines such as MCF7 cells [36], and it was increased, together with superoxide dismutase,
catalase, and GST-pi, in non-small cell lung cancer A549 cells [98]. The different rate and pathways of
DHA uptake and metabolism, as well as the plethora of different transcriptional factors, co-activators,
and co-repressors affecting the expression of antioxidant enzymes, may account for the variable effects
of the sameω-3 LCPUFAs in different cell models.
It seems clear thatω-3 LCPUFAs are not general MDR reversing agents, but they may overcome
the resistance in a chemotherapeutic agent- and tumor type-dependent way. Their chemosensitizing
effects are sometimes also independent from the changes in plasma membrane lipid composition and in
drug-metabolizing enzymes. For instance, DHA reversed the resistance to cisplatin in a small cell lung
carcinoma cell line by enhancing the formation of DNA inter-strand cross-links [28]. The resistance
to gemcitabine in pancreatic cancer is specifically associated with the increased ratio between the
pro-survival NF-κB transcription factor and the pro-apoptotic protein poly (ADP-ribose) polymerase
(PARP): sinceω-3 LCPUFAs inhibited NF-κB and activated PARP, they were particularly suitable in
restoring gemcitabine cytotoxicity in this model [99].
The effects ofω-3 LCPUFAs on specific tumor subpopulations and/or on tumor stromal cells may
represent additional factors contributing to MDR reversion. Cancer stem cells are the most resistant
component of the tumor bulk and are often responsible for tumor relapses. Recently, EPA has been
found to increase cell differentiation and deplete cancer stem cells from the colorectal COLO 320
DM cell line: these events restored the efficacy of oxaliplatin and 5-fluorouracil in differentiated and
stem cell populations, and chemosensitized stem cells subpopulation to 5-fluorouracil [13]. It has
not been investigated whether the chemosensitizing effect in cancer stem cells is shared with other
tumor types; in the case of a positive answer, this could represent an added value of ω-3 LCPUFAs as
chemosensitizer agents.
Aggressive tumors have often a fast and disordered growth that is not adequately supported
by the tumor vasculature: the reduced supply of blood and oxygen limits delivery and activity of
chemotherapeutic drugs. By modulating the endothelial synthesis of nitric oxide, ω-3 LCPUFAs
increased tumor vasculature and improved the delivery and extravasation of docetaxel in rats bearing
drug-resistant mammary tumors [100]. A similar effect was observed in rats with epirubicin resistant
mammary tumors treated with DHA [101]: in this model, however,ω-3 LCPUFAs decreased tumor
vascularization, suggesting an anti-angiogenic effect of ω-3 LCPUFAs. Since ω-3 LCPUFAs were
administered before chemotherapy, two sequential mechanisms may occur in this case: the reduced
angiogenesis exerted byω-3 LCPUFAs can decrease the tumor bulk; such a reduction can make the
tumor more eradicable by the subsequent administration of epirubicin. In a neuroblastoma xenograft
model, fish oil did not reduce the microvesssel density when administered alone, but it did so when
co-administered with sunitinib [102]; in the same condition, fish oil altered the production of local
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eicosanoids and decreased tumor-associated inflammatory cells, which may include tumor associated
macrophages type I. The sum of all these effects produced a significant reduction in tumor growth [102].
Although contrasting in mechanisms, these studies suggest thatω-3 LCPUFAs share the properties
of reversing drug resistance in vivo through concurrent mechanisms targeting both either tumor cells
or tumor microenvironment.
6. ω-3 LCPUFAs as Revertants of Multidrug Resistance: Preclinical and Clinical Studies
Curiously, several studies have demonstrated the chemosensitizing efficacy of LCPUFAs in
pre-clinical models before in vitro studies investigated the molecular mechanisms at the basis of such
chemosensitization. Despite the differences in the amount, type, and proportion of ω-3 and ω-6
LCPUFAs, all in vivo studies reported that the dietary supplementation with ω-3 LCPUFAs improved
the efficacy of chemotherapy in solid and hematologic xenograft tumors [6,10,12,18,102,103] and in
spontaneously developing or syngeneic tumors [100,101]. This effect was also valid in advanced tumor
stages: for instance, dogs fed with menhaden fish oil and arginine before and after remission of Stage
III lymphoblastic lymphoma showed prolonged disease free survival and overall survival compared
with animals fed with a standard diet [104].
When given separately and not in a mixture like fish oil, the effects ofω-3 LCPUFAs are, however,
more controversial: for instance, whereas DHA alone enhanced the efficacy of epothilone but not the
efficacy of 5-fluorouracil and cyclophosphamide, and EPA produced the opposite effect, neither DHA
nor EPA increased the antitumor efficacy of gemcitabine in mice bearing colon cancers [105].
Compared with the administration of a singleω-3 LCPUFA, the supplementation with a mixture
alters the balance between SFAs and LCPUFAs more deeply within tumor tissues. The changes in the
membrane lipid environment, the increase of lipid peroxidation products, and the modifications of
eicosanoids produced in tumor stroma—three possible mechanisms of chemosensitization—are more
pronounced afterω-3 LCPUFA mixture than a singleω-3 LCPUFA administration. This difference may
explain why the dietary supplementation with fish oil improved the efficacy towards many different
chemotherapeutic drugs, whereas the supplementation with singleω-3 LCPUFA had doubtful efficacy.
The presence of other nutritional supplements may represent an additional confounding factor:
for instance, the supplementation with ω-3 LCPUFAs or glutamine as single agents increased the
efficacy of 5-fluorouracil in colon cancer bearing mice, but this event was surprisingly reduced by
their simultaneous administration [106]. Moreover, the schedule of ω-3 LCPUFA administration
widely varies between each work, making difficult the comparison between preclinical studies. Most
protocols gaveω-3 LCPUFAs immediately after the tumor implantation and before chemotherapy and
continued with a combined administration ofω-3 LCPUFAs and chemotherapy [6,10,12,18,100,101].
The administration ofω-3 LCPUFAs before or together sunitinib did not produce significant differences
in the growth of neuroblastoma xenografts [102], but the comparison between different protocols of
ω-3 LCPUFAs and chemotherapy administration has not been performed in other tumor models,
leaving several issues uninvestigated. Whether the preventive supplementation of ω-3 LCPUFAs
reduces the onset of chemoresistance and whether the administration of ω-3 LCPUFAs at tumor
diagnosis or during tumor recurrences are equally effective in overcoming MDR are still unresolved
questions. Only when these questions are answered can more precise information about the most
effective scheme ofω-3 LCPUFA administration be inferred.
One interesting finding obtained from in vivo studies is that the supplementation with
ω-3 LCPUFAs increased the benefits of chemotherapy in both drug-sensitive [103,106,107] and
drug-resistant tumors [6,18,101,105,107,108]: in the latter, however,ω-3 LCPUFAs usually produced
stronger benefits in terms of tumor regression or stabilization. The higher efficacy ofω-3 LCPUFAs in
chemoresistant tumors may be explained by their greater cholesterol synthesis and peculiar membrane
lipid composition that affects ABC transporter expression and activity [73].
One pioneering clinical study reported a direct correlation between the positive response to
chemotherapy and the high level ofω-3 LCPUFAs, in particular DHA, in adipose breast tissue [109].
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This study suggested the possibility that raising the concentration of LCPUFAs might improve
chemotherapy efficacy and opened the way to clinical trials investigating the effects ofω-3 LCPUFA
supplementation in patients subjected to chemotherapy.
A Phase II trial in patients with metastatic breast cancer showed that the daily supplementation
with DHA was well-tolerated in patients receiving anthracycline-based chemotherapy and produced
a significant increase in the overall survival, which was directly correlated with blood DHA
concentration [110].
Being often refractory to standard chemotherapy, non-small cell lung cancer is a tumor under
intensive investigation for the development of new therapeutic approaches. Interestingly, in non-small
cell lung cancer patients, first-line chemotherapy supplemented with fish oil improved the clinical
response and the overall survival, without increasing the burden of chemotherapy-induced side
effects [111]. Since the fish oil supplements used in the study included 2.2 g of EPA and 240–500 mg
of DHA, the therapeutic benefit was likely attributable to both LCPUFAs. The adequate intake of
ω-3 LCPUFA ranges from 1.1 to 1.6 g/day in adults, with at least 10% DHA and EPA. Although the
amount of DHA and EPA given in the above-cited study was higher than the average adequate intake
recommended in a standard Western diet, this amount was well also tolerated by debilitated patients,
such as patients undergoing chemotherapy treatment. The lack of adverse effects of ω-3 LCPUFAs
and/or the attenuation of the chemotherapy side effects [109,111] are added values that make the
compliance of patients in the clinical studies relatively high. The amount and types of LCPUFAs
necessary to achieve therapeutic benefits in cardiovascular diseases and dyslipidemic syndromes are
well known by clinicians. Such experience reduces the difficulty of translating the administration
of LCPUFAs to other clinical settings, such as those of oncological diseases. The low cost of ω-3
LCPUFAs [112] compared with the costs of the targeted therapies used in patients unresponsive to
conventional chemotherapy is another appealing factor that makes ω-3 LCPUFA supplementation
particularly suitable for large population studies.
An alternative to the DHA administration and chemotherapy as single agents is the use of a
multitarget conjugate of DHA and chemotherapeutic drug. Two independent trials reported that a
DHA-paclitaxel conjugate induced less side effects than free paclitaxel in patients with resistant solid
tumors, owing to the different pharmacokinetic profile of paclitaxel released from DHA [113,114];
the conjugate also produced a good stabilization of the tumor in patients refractory to previous
chemotherapeutic regimens [114]. The kinetic profile has not been investigated in these studies,
and mechanisms of DHA dissociates from paclitaxel: since the two agents are bound by an acyl
link [115], it is likely that plasma esterases released DHA from paclitaxel and that the observed tumor
stabilization was due to the chemosensitizing effect of DHA on resistant cells. Compared with single
agents, multitarget drugs have a lower risk of drug–drug interaction, a better compliance for patients
and a more predictable pharmacokinetic profile: given the good chemosensitization efficacy achieved
by the DHA-paclitaxel conjugate, this approach may represent a useful tool for future Phase II and
Phase III trials.
7. Concluding Remarks
Despite a certain variability in the mechanisms, types, doses, and schedule of ω-3 LCPUFA
administration, most studies have demonstrated that DHA and EPA improve the efficacy of
chemotherapy in vitro and in vivo. It is noteworthy that the chemoresistance is higher, and the
chemosensitizing effect is also higher and is a feature that is uncommon for other MDR reversing
agents or ABC transporter inhibitors. Moreover, ω-3 LCPUFA supplementation was generally
well tolerated and did not increase the side effects of chemotherapy: some studies indeed have
reported a reduction of tumor-related or chemotherapy-related side effects, such as cachexia [10],
osteoporosis [116], neutropenia [18], cardiotoxicity [117], and diarrhea [12,106]. LCPUFA uptake by
tumor and non-tumor cells is highly variable [110,118], leading to rule out that the antitumor effects
of LCPUFAs only depend on the higher uptake of LCPUFA in tumor cells. It is well-known that
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LCPUFAs change the lipid membrane composition of transformed and non-transformed cells in a
different way [119], and that the membrane composition of drug-sensitive and drug-resistant cells is
different, the latter being richer of cholesterol and lipid rafts [76]. It is likely that the incorporation
of ω-3 LCPUFAs, which lower plasma membrane cholesterol and disrupt lipid raft architecture,
impairs the activity of membrane proteins more in drug-resistant cells than in drug-sensitive cells or
in non-transformed cells. This may explain why the chemosensitizing effects ofω-3 LCPUFAs were
often more pronounced in MDR cells.
In addition, ω-3 LCPUFAs target specific metabolic pathways that are necessary for the
maintenance of the MDR phenotype [73]. The search for compounds exerting a selective cytotoxicity
in MDR cells—an event known as “collateral sensitivity” [120]—is very active. ROS inducers, ATP
depleting agents, detergents increasing membrane fluidity are the most promising agents in this
new generation of MDR reversing tools [120]. However, the potential toxicity of these compounds
in non-transformed cells raises some doubts about their extensive use in vivo. ω-3 LCPUFAs are a
step over these “collateral sensitivity” inducers, because they are more effective in MDR cells and
well-tolerated in patients.
A considerable number of in vivo studies have shown a good chemosensitizing effect of ω-3
LCPUFAs in tumors resistant to anthracyclines and taxanes [18,100,101,110,113,114], two classes of
drugs widely used in both hematological and solid malignancies. This feature enlarges the potential
number of oncological patients who may benefit fromω-3 LCPUFA supplementation, compared with
other MDR reversing compounds, and makes the realization of Phase III trials easier.
On the other hand, although in vitro and in vivo studies highlighting the therapeutic benefits of
ω-3 LCPUFAs have been abundant in the last two decades, several issues must still be clarified, before
their extensive use in clinical practice is proposed. First, most attention has been focused on the effects
ofω-3 LCPUFAs on the lipid plasma membrane and plasma-membrane-associated proteins. LCPUFAs
can be theoretically incorporated in all cell membranes, thus affecting the lipidomic/proteomic profile
of the endoplasmic reticulum, the Golgi apparatus, endosome/exosome vesicles, mitochondria, and the
nucleus. In all these organelles, transmembrane proteins regulate crucial biological functions; the extent
of LCPUFA incorporation in these intracellular membranes and the impact on the physiological
organelle activity are a subject largely unexplored. Specific investigations in the field may unveil new
mechanisms at the basis of antitumor and MDR reversing efficacy ofω-3 LCPUFAs.
In contrast with most evidence showing that LCPUFAs chemosensitize cancer cells,
a recent work reported that cisplatin-treated colon carcinoma became resistant to different
chemotherapeutic drugs following the cisplatin-induced production of two endogenous LCPUFAs,
namely 12-oxo-5,8,10-heptadecatrienoic acid and hexadeca-4,7,10,13-tetraenoic acid (16:4, ω-3),
by mesenchymal stem cells [121]. This work is the only one reporting that endogenous ω-3 LCPUFAs,
in contrast with the exogenously administered ones, have a deleterious effect on chemotherapy efficacy,
opening a second field of investigation that is actually unexplored.
A third issue poorly known is represented by the inter-individual differences in LCPUFA
absorption, by the genetic polymorphisms in the enzymes involved in fatty acid uptake, transport, and
metabolism, and by the amount and types of other fatty acids present in the patient diet. In light of
these factors, a careful optimization of theω-3 LCPUFA supplementation protocol, tailored to single
patients, might be required. At present, how such inter-individual differences affect ω-3 LCPUFA
efficacy is not known; only large population studies will likely clarify these points. The safety and the
low cost ofω-3 LCPUFA supplementation may be advantageous in realizing such studies, increasing
the confidence that most of the open questions concerning mechanisms and benefits of LCPUFAs as
chemosensitizing agents will be solved soon.
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